Metastatic urothelial bladder cancer

Scale, severity and unmet need

Bladder cancer is the fifth most common form of cancer in Europe and the US with heavy social costs and poor prognosis for patients with metastatic forms of the disease. Current treatments are associated with limited efficacy and severe side effects. Explore the condition, therapies and which stage of the disease MFA-370 is being developed to treat.

Bladder cancer: the big picture


The 5th most common cancer in the US and EU


New cases globally every year (1)


One of highest recurrence rates
50-70% recur, 10-20% of these progress to metastatic disease


At least 90% of Bladder Cases are of urothelial origin


The most expensive cancer to treat
US cost of cases for 2020 – 173 BUSD


Unmet need high
Current treatments are all hospital-based:
LOW efficacy
HIGH cost
SEVERE side effects

  • 1.Richters, A., Aben, K.K.H. & Kiemeney, L.A.L.M. The global burden of urinary bladder cancer: an update. World J Urol 38, 1895–1904 (2020).

Which mUBC patients will be prescribed MFA-370?

Current treatments for metastatic forms of mUBC have limited efficacy, involve severe side effects and require frequent, long hospital visits that disrupt quality of life and incur high social costs. At what stage of the disease will MFA-370 be used in trial, and in the future?

  • MFA-370 is being developed to treat patients who have metastatic urothelial bladder cancer that has progressed following first-line treatments with platinum-based chemotherapy and / or second-line checkpoint inhibitors.
  • MFA-370 can also be used to treat patients who have chosen not to undergo, or are unable to undergo, standard therapy.

Today, this patient population consists of people beginning third-line treatment in countries where the Company has approved and issued patent.

The total target population in US, EU4 and UK based on these criteria was approximately 7,296 patients 2022, with an estimated market potential for third line treatment estimated to  USD 822 M and CAGR (2022-2030) of 3.3% (1).

(1) Datamonitor (2022) Epidemiology

MFA-370: our vision

Ectin’s vision is to be able to offer patients with cancer an effective treatment that has fewer and milder potential side effects than today’s established treatments.

In preclinical studies, MFA-370 has shown that the treatment can induce decreased cancer cell proliferation as well as specifically induce cancer cell death. MFA-370 will first be trialed in mUBC patients. Ultimately Ectin aims to develop MFA-370 into a new standard treatment not only for third-line patients who have already undergone standard therapy, but after approval for treatment of third-line patients go for patients in lower treatment lines also.

MFA-370 will be developed to be administered in the patient’s home, which means less disruption, travel and dependence on medical care for patients and lower social costs.